-
11.发明申请公开(公告)号：US20220119366A1
公开(公告)日：2022-04-21
申请号：US17228815
申请日：2021-04-13
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun Ma , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D405/14 , C07D409/14 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US20210238188A1
公开(公告)日：2021-08-05
申请号：US17155159
申请日：2021-01-22
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yong He , Xuechao Xing , Guoqiang Wang , Ruichao Shen , Brett Granger , Jiang Long , Yat Sun Or
IPC: C07D491/048 , A61K45/06
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
公开(公告)号：US10988458B2
公开(公告)日：2021-04-27
申请号：US16866778
申请日：2020-05-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10829486B2
公开(公告)日：2020-11-10
申请号：US16272506
申请日：2019-02-11
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Ruichao Shen , Jun Ma , Guoqiang Wang , Xuechao Xing , Yat Sun Or
Abstract: The present invention provides compounds of Formula (I): pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
-
公开(公告)号：US20200317717A1
公开(公告)日：2020-10-08
申请号：US16854334
申请日：2020-04-21
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Brett Granger , Xuechao Xing , Yat Sun Or
Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),
-
Patent Agency Ranking
公开(公告)号：US10696713B2
公开(公告)日：2020-06-30
申请号：US16222380
申请日：2018-12-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US20190194216A1
公开(公告)日：2019-06-27
申请号：US16217749
申请日：2018-12-12
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Jun Ma , Guoqiang Wang , Xuechao Xing , Ruichao Shen , Bin Wang
IPC: C07D491/048 , C07D493/04 , C07D487/04 , C07D417/14
CPC classification number: C07D491/048 , C07D417/14 , C07D487/04 , C07D493/04
Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10246483B2
公开(公告)日：2019-04-02
申请号：US15041811
申请日：2016-02-11
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Ruichao Shen , Yat Sun Or , Guoqiang Wang
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US10246439B2
公开(公告)日：2019-04-02
申请号：US15988783
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jun Ma , Xuechao Xing , Jing He , Yong He , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D487/08 , C07D491/08 , C07D513/04 , C07D417/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
20.发明申请公开(公告)号：US20190062310A1
公开(公告)日：2019-02-28
申请号：US16113611
申请日：2018-08-27
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Jing He , Bin Wang , Ruichao Shen , Brett Granger , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D471/04
CPC classification number: C07D401/14 , A61P1/16 , A61P3/10 , A61P13/12 , C07D413/14 , C07D471/04
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
-
-
-
-
-
-
-
-
Search Results
154
records
(took 0.034 seconds)
